HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ulonivirine

Also Known As:

3-chloro-5-(6-oxo-1-((6-oxo-5-(trifluoromethyl)-1H-pyridazin-3-yl)methyl)-4-(trifluoromethyl)pyrimidin-5-yl)oxy-benzonitrile; MK-8507

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - ulonivirine: 3
  - Pyridazines: 11
    - ulonivirine: 3

Experts

1.	Iwamoto, Marian: 3 articles (01/2022 - 11/2021)
2.	Jackson Rudd, Deanne: 3 articles (01/2022 - 11/2021)
3.	Schaeffer, Andrea: 3 articles (01/2022 - 11/2021)
4.	Stoch, S Aubrey: 3 articles (01/2022 - 11/2021)
5.	Ankrom, Wendy: 2 articles (01/2022 - 11/2021)
6.	Friedman, Evan J: 2 articles (01/2022 - 11/2021)
7.	Tomek, Charles: 2 articles (01/2022 - 11/2021)
8.	Zhang, Saijuan: 2 articles (01/2022 - 01/2022)
9.	De Lepeleire, Inge: 1 article (01/2022)
10.	Däumer, Martin: 1 article (01/2022)

Related Diseases

1.

01/01/2022 - "MK-8507 PKs were generally dose-proportional and similar to observations in participants without HIV-1 infection in prior studies; mean MK-8507 half life was 56-69 hours in this study. "
11/17/2021 - "The pharmacokinetics and safety data are supportive of once-weekly oral administration and support further clinical investigation of MK-8507 for the treatment of HIV-1 infection."
01/01/2022 - "MK-8507 is an investigational HIV-1 nonnucleoside reverse transcriptase inhibitor being developed for the treatment of HIV-1 infection. "
11/17/2021 - "MK-8507 is a novel HIV-1 nonnucleoside reverse transcriptase inhibitor in clinical development with potential for once-weekly oral administration for the treatment of HIV-1 infection. "
01/01/2022 - "MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. "

Related Drugs and Biologics

1.	Reverse Transcriptase Inhibitors
2.	Nucleosides

Related Therapies and Procedures

1.	Oral Administration